Lixte Biotechnology Holdings, Inc. (LIXT)
Company Description
Lixte Biotechnology Holdings, Inc. operates as a drug discovery company that uses biomarker technology to design novel compounds for serious common diseases.
The company primarily focuses on inhibitors of protein phosphatases that are used alone and in combination with cytotoxic agents and/or x-ray and immune checkpoint blockers; and encompasses two major categories of compounds at various stages of pre-clinical and clinical development.
It develops two series of pharmacologically active drugs, which include the LB-100 series that consists of novel structures for the treatment of cancers, and vascular and metabolic diseases; and LB-200 series to treat chronic hereditary diseases, such as Gaucher's disease, as well as cancer and neurodegenerative diseases.
Lixte Biotechnology Holdings, Inc. has a clinical trial research agreement with the Moffitt Cancer Center and Research Institute Hospital Inc.; collaboration agreement for an investigator-initiated clinical trial with the Spanish Sarcoma Group, as well as Netherlands Cancer Institute and Oncode Institute.
Lixte Biotechnology Holdings, Inc. was founded in 2005 and is based in Pasadena, California.
Country | United States |
Founded | 2005 |
Industry | Biotechnology |
Sector | Healthcare |
Employees | 3 |
CEO | Bastiaan van der Baan M.Sc. |
Contact Details
Address: 248 Route 25a, No. 2 East Setauket, New York 11733 United States | |
Phone | 310 203 2902 |
Website | lixte.com |
Stock Details
Ticker Symbol | LIXT |
Exchange | NASDAQ |
Fiscal Year | January - December |
Reporting Currency | USD |
CIK Code | 0001335105 |
CUSIP Number | 539319202 |
ISIN Number | US5393193017 |
Employer ID | 20-2903526 |
SIC Code | 2834 |
Key Executives
Name | Position |
---|---|
Bastiaan van der Baan M.Sc. | President, Chief Executive Officer and Chairman of the Board of Directors |
Robert Neal Weingarten | Vice President and Chief Financial Officer |
Eric J. Forman J.D. | Vice President and Chief Operating Officer |
Dr. James S. Miser M.D. | Chief Medical Officer |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Mar 28, 2024 | 8-K | Current Report |
Mar 22, 2024 | 8-K | Current Report |
Mar 19, 2024 | 10-K | Annual Report |
Feb 27, 2024 | 8-K | Current Report |
Feb 26, 2024 | 8-K | Current Report |
Jan 30, 2024 | 8-K | Current Report |
Nov 28, 2023 | 8-K | Current Report |
Nov 13, 2023 | 8-K | Current Report |
Nov 9, 2023 | 10-Q | Quarterly Report |
Oct 17, 2023 | 8-K | Current Report |